Micrograph of<unk>  demonstrating characteristic psammoma bodies and cilia. H&E stain. Characteristic discohesiveness of cells (like falling apart) around fibrovascular cores. The lesion is found in patients who present typically with abnormal or postmenopausal bleeding. Such bleeding is followed by further evaluation leading to a tissue diagnosis, usually done by a dilatation and curettage. A work-up to follow would look for metastasis using imaging technology including sonography and magnetic resonance imaging. The median age at diagnosis in a study of 138 women was 67 years, of these 54 had stage I, 20 stage II, 41 stage III, and 23 stage IV disease. Histopathologically,<unk> s is typically characterized by (1) nipple-shaped structures (papillae) with fibrovascular cores (2) marked nuclear atypia (irregularities in the nuclear membrane, enlarged nuclear size), (3) psammoma bodies and (4) cilia. Staging Micrograph showing (malignant) peritoneal cytopathology<unk>  carcinoma), indicating at least Stage IIIA disease. Uterine papillary<unk>  carcinoma is staged like other forms of endometrial carcinoma at time of surgery using the International Federation of Gynecology and Obstetrics cancer staging system. *Stage IA: tumor is limited to less than half the myometrium *Stage IB: invasion of more than half the myometrium *Stage II: cervical stromal invasion *Stage IIIA: tumor invades<unk> a or adnexa *Stage IIIB: vaginal or parametrial metastasis *Stage IIIC1: metastasis to pelvic lymph nodes *Stage IIIC2: metastasis to para-aortic lymph nodes *Stage IVA: invasion of the bladder or bowel *Stage IVB: distant metastasis, including intra-abdominal or inguinal lymph nodes Survival In the older literature survival rates have been given as 35–50% for stage I–II and 0–15% for stage III and IV uterine papillary<unk>  carcinoma, More recently it was reported that forty-two percent of 138 patients were found disease-free at five years. In 2009, the journal of "Gynecologic Oncology" reported the following 5-year survival rates based upon stage of cancer: *Stage I: 50% - 80% *Stage II: 50% *Stage III: 20% *Stage IV: 5% - 10%
Uterine serous carcinoma
Endometrial stromal sarcoma
Uterine sarcoma
Endometrial stromal tumour
Uterine adenosarcoma
Uterine clear-cell carcinoma
Leiomyosarcoma
Endometrioid tumor